Electronics
Health
Technology

Senseonics

$2.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Senseonics and other stocks, options, ETFs, and crypto commission-free!

About

Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. Read More The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Employees
192
Headquarters
Germantown, Maryland
Founded
2014
Market Cap
461.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.85M
High Today
$2.66
Low Today
$2.51
Open Price
$2.60
Volume
1.33M
52 Week High
$5.29
52 Week Low
$2.15

Collections

Electronics
Health
Technology
Medical
US
North America

News

Yahoo FinanceMar 25

Senseonics Unveils Eversense Bridge Program in the U.S.

Senseonics Holdings, Inc. SENS recently announced the commercial launch of the Eversense Bridge Patient Access Program in the United States. This program will enable diabetic patients access the company’s newly-approved Eversense continuous glucose monitoring (CGM) system, for $99, in addition to the cost of sensor placement. The program is in sync with Senseonics’ strategy to offer advanced and affordable medical care to diabetic patients. Senseonics is a global medical technology company specializing in...

312
Seeking AlphaMar 22

Senseonics launches the Eversense access program in U.S.

Senseonics Holdings (NYSEMKT:SENS) has launched the Eversense Bridge Program in U.S. Under the program, patients can access the Eversense continuous glucose monitoring (CGM) System, the only long-term CGM that lasts up to 90 days, for only $99* plus the cost of the sensor placement by the healthcare provider....

403
Seeking AlphaMar 5

Senseonics Eversense CGM integrates with Glooko

Senseonics Holdings (NYSEMKT:SENS) announces the integration of Eversense CGM data into the Glooko diabetes data management platform.

1,124

Earnings

-$0.16
-$0.12
-$0.08
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.14 per share
Actual
-$0.04 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.